- Details emerge on a possible ViroPharma (VPHM +27.4%) sale after Bloomberg initially reported the firm had hired Goldman to help it evaluate its options.
- Citing sources, Bloomberg identifies Sanofi (SNY +0.1%) and Shire (SHPG +1.1%) as the interested parties.
- Meanwhile, the Street is busy trying to nail the valuation.
- Mark Deutsche down for $46-52/share.
- More on the prospective deal here